Ichor Life Sciences
A US-based, full-service preclinical contract research organization (CRO) providing integrated drug discovery and preclinical development capabilities. Services include protein expression and structural biology, biophysical and biochemical assay development, in vitro and in vivo pharmacology (including vivarium operations and disease models), and clinical trial support. The company emphasizes in-house method development, translational R&D in aging and ophthalmology, and partnerships with academic institutions.
Industries
Nr. of Employees
medium (51-250)
Ichor Life Sciences
Lafayette, Louisiana, United States, North America
Products
Orally bioavailable protein binding scaffold (epitope tag)
A small, stable protein scaffold derived from extremophile ribose-binding proteins engineered as an orally bioavailable epitope tag and binding scaffold; used for targeting and assay development.
Custom SPR biosensor chip technology
Optical biosensor chip and SPR workflows for direct target capture from lysate and kinetic characterization to streamline binding studies.
Orally bioavailable protein binding scaffold (epitope tag)
A small, stable protein scaffold derived from extremophile ribose-binding proteins engineered as an orally bioavailable epitope tag and binding scaffold; used for targeting and assay development.
Custom SPR biosensor chip technology
Optical biosensor chip and SPR workflows for direct target capture from lysate and kinetic characterization to streamline binding studies.
Services
End-to-end protein biology services including expression, purification, structural biology, and biophysical characterization.
In vitro and in vivo pharmacology, assay development, PK/PD, histology, and disease model development to support lead optimization and preclinical programs.
Clinical trial preparation and management services including protocol design, site qualification, recruitment, and close-out support.
Advisory services for animal research and laboratory operations.
End-to-end protein biology services including expression, purification, structural biology, and biophysical characterization.
In vitro and in vivo pharmacology, assay development, PK/PD, histology, and disease model development to support lead optimization and preclinical programs.
Clinical trial preparation and management services including protocol design, site qualification, recruitment, and close-out support.
Advisory services for animal research and laboratory operations.
Expertise Areas
- Protein expression and purification
- Structural biology
- Biophysical and biochemical assay development
- In vivo pharmacology and toxicology
Key Technologies
- Recombinant protein expression (bacterial, yeast, insect, mammalian)
- X-ray crystallography
- Surface plasmon resonance (SPR)
- Bio-layer interferometry (BLI)
News & Updates
Announcement of launch of clinical trial services to provide protocol design, site identification, recruitment strategies, and full clinical trial management.
Expansion of clinical trial services to Australia, Europe, and the United Kingdom through collaborative processes with regional CROs.
Peer-reviewed article investigating coevolution of the Ess1-CTD axis and suggesting roles for phase separation in cold tolerance; collaboration with SUNY-Upstate Medical University.
Participation in peer-reviewed research on development and validation of a protein nanopore sensor for detection of a chromatin-associated protein, demonstrating single-molecule detection approaches.
Completed acquisition and integration of an in vivo CRO to expand in vivo pharmacology and metabolic disease capabilities.
Company founded in 2013 from an initial residential laboratory with subsequent commercial expansion to multiple facilities in upstate New York.
Announcement of launch of clinical trial services to provide protocol design, site identification, recruitment strategies, and full clinical trial management.
Expansion of clinical trial services to Australia, Europe, and the United Kingdom through collaborative processes with regional CROs.
Peer-reviewed article investigating coevolution of the Ess1-CTD axis and suggesting roles for phase separation in cold tolerance; collaboration with SUNY-Upstate Medical University.
Participation in peer-reviewed research on development and validation of a protein nanopore sensor for detection of a chromatin-associated protein, demonstrating single-molecule detection approaches.
Completed acquisition and integration of an in vivo CRO to expand in vivo pharmacology and metabolic disease capabilities.
Company founded in 2013 from an initial residential laboratory with subsequent commercial expansion to multiple facilities in upstate New York.